{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T22:11:39Z","timestamp":1792188699794,"version":"4.4.0"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,1,4]],"date-time":"2022-01-04T00:00:00Z","timestamp":1641254400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,1,4]],"date-time":"2022-01-04T00:00:00Z","timestamp":1641254400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cannabis Res"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Introduction<\/jats:title>\n                <jats:p>Palliative care aims to improve quality of life through optimal symptom control and pain management<jats:bold>.<\/jats:bold> Cannabis-based medicinal products (CBMPs) have a proven role in the treatment of chemotherapy-induced nausea and vomiting. However, there is a paucity of high-quality evidence with regards to the optimal therapeutic regimen, safety, and effectiveness of CBMPs in palliative care, as existing clinical trials are limited by methodological heterogeneity. The aim of this study is to summarise the outcomes of the initial subgroup of patients from the UK Medical Cannabis Registry who were prescribed CBMPs for a primary indication of palliative care, cancer pain and chemotherapy-induced nausea and vomiting, including effects on health-related quality of life and clinical safety.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A case series from the UK Medical Cannabis Registry of patients, who were receiving CBMPs for the indication of palliative care was undertaken. The primary outcome consisted of changes in patient-reported outcome measures including EQ-5D-5L, General Anxiety Disorder-7 (GAD-7), Single-Item Sleep Quality Scale (SQS), Pain Visual Analog Scale (VAS) and the Australia-Modified Karnofsky Performance Scale at 1 and 3\u2009months compared to baseline. Secondary outcomes included the incidence and characteristics of adverse events. Statistical significance was defined by <jats:italic>p<\/jats:italic>-value&lt;\u20090.050.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Sixteen patients were included in the analysis, with a mean age of 63.25\u2009years. Patients were predominantly prescribed CBMPs for cancer-related palliative care (<jats:italic>n<\/jats:italic>\u2009=\u200915, 94%). The median initial CBD and THC daily doses were 32.0\u2009mg (Range: 20.0\u2013384.0\u2009mg) and 1.3\u2009mg (Range: 1.0\u201316.0\u2009mg) respectively. Improvements in patient reported health outcomes were observed according to SQS, EQ-5D-5L mobility, pain and discomfort, and anxiety and depression subdomains, EQ-5D-5L index, EQ-VAS and Pain VAS validated scales at both 1-month and 3-months, however, the changes were not statistically significant. Three adverse events (18.75%) were reported, all of which were either mild or moderate in severity.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>This small study provides an exploratory analysis of the role of CBMPs in palliative care in the first cohort of patients since CBMPs legalisation in the UK. CBMPs were tolerated with few adverse events, all of which were mild or moderate and resolved spontaneously. Further long-term safety and efficacy studies involving larger cohorts are needed to establish CBMPs role in palliative care, including comparisons with standard treatments.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s42238-021-00114-9","type":"journal-article","created":{"date-parts":[[2022,1,4]],"date-time":"2022-01-04T03:02:33Z","timestamp":1641265353000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["UK Medical Cannabis Registry palliative care patients cohort: initial experience and outcomes"],"prefix":"10.1186","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8502-4364","authenticated-orcid":false,"given":"Devaki","family":"Nimalan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michal","family":"Kawka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Erridge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet","family":"Ergisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Harris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Salazar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rayyan","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katerina","family":"Loupasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl","family":"Holvey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ross","family":"Coomber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Platt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James J.","family":"Rucker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaheen","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikael H.","family":"Sodergren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,4]]},"reference":[{"issue":"1","key":"114_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/1472-684X-4-7","volume":"4","author":"A Abernethy","year":"2005","unstructured":"Abernethy A, Shelby-James T, Fazekas B, Woods D, Currow D. The Australia-modified Karnofsky performance status (AKPS) scale: a revised scale for contemporary palliative care clinical practice. BMC Palliative Care. 2005;4(1):7.","journal-title":"BMC Palliative Care"},{"issue":"8","key":"114_CR2","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1093\/annonc\/mdp001","volume":"20","author":"H Breivik","year":"2009","unstructured":"Breivik H, Cherny N, Collett B, de Conno F, Filbet M, Foubert AJ, et al. Cancer-related pain: a pan-European survey of prevalence, treatment, and patient attitudes. Ann Oncol. 2009;20(8):1420\u201333. https:\/\/doi.org\/10.1093\/annonc\/mdp001.","journal-title":"Ann Oncol"},{"key":"114_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/npr2.12183","volume":"41","author":"S Erridge","year":"2021","unstructured":"Erridge S, Salazar O, Kawka M, et al. An initial analysis of the UK medical cannabis registry: outcomes analysis of first 129 patients. Neuropsychopharmacol Rep. 2021;41:1\u20139.","journal-title":"Neuropsychopharmacol Rep"},{"key":"114_CR4","doi-asserted-by":"publisher","first-page":"S240","DOI":"10.1002\/acr.20543","volume":"63","author":"G Hawker","year":"2011","unstructured":"Hawker G, Mian S, Kendzerska T, French M. Measures of adult pain: visual analog scale for pain (VAS pain), numeric rating scale for pain (NRS pain), McGill pain questionnaire (MPQ), short-form McGill pain questionnaire (SF-MPQ), chronic pain grade scale (CPGS), short Form-36 bodily pain scale (SF-36 BPS), and measure of intermittent and constant osteoarthritis pain (ICOAP). Arthritis Care Res. 2011;63:S240\u201352.","journal-title":"Arthritis Care Res"},{"issue":"10","key":"114_CR5","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1007\/s11136-011-9903-x","volume":"20","author":"M Herdman","year":"2011","unstructured":"Herdman M, Gudex C, Lloyd A, et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res. 2011;20(10):1727\u201336.","journal-title":"Qual Life Res"},{"key":"114_CR6","doi-asserted-by":"publisher","first-page":"2899","DOI":"10.3892\/mmr.2016.5585","volume":"14","author":"WJ Huang","year":"2016","unstructured":"Huang WJ, Chen WW, Zhang X. Endocannabinoid system: role in depression, reward and pain control (review). Mol Med Rep. 2016;14:2899\u2013903 Spandidos Publications.","journal-title":"Mol Med Rep"},{"issue":"3","key":"114_CR7","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1097\/MLR.0b013e318160d093","volume":"46","author":"B L\u00f6we","year":"2008","unstructured":"L\u00f6we B, Decker O, M\u00fcller S, et al. Validation and standardization of the generalized anxiety disorder screener (GAD-7) in the general population. Med Care. 2008;46(3):266\u201374.","journal-title":"Med Care"},{"issue":"6","key":"114_CR8","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1002\/phar.2115","volume":"38","author":"EA Romero-Sandoval","year":"2018","unstructured":"Romero-Sandoval EA, Fincham JE, Kolano AL, Sharpe BN, Alvarado-V\u00e1zquez PA. Cannabis for chronic pain: challenges and considerations. Pharmacotherapy. 2018;38(6):651\u201362.","journal-title":"Pharmacotherapy"},{"issue":"11","key":"114_CR9","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.5664\/jcsm.7478","volume":"14","author":"E Snyder","year":"2018","unstructured":"Snyder E, Cai B, DeMuro C, Morrison MF, Ball W. A new single-item sleep quality scale: results of psychometric evaluation in patients with chronic primary insomnia and depression. J Clin Sleep Med. 2018;14(11):1849\u201357.","journal-title":"J Clin Sleep Med"},{"key":"114_CR10","volume-title":"Palliative care","author":"World Health Organization","year":"2020","unstructured":"World Health Organization. Palliative care; 2020. [cited 2021 Jul 4]. Available from: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/palliative-care#:~:text=Each year%2C an estimated 40,palliative care currently receive it"}],"container-title":["Journal of Cannabis Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s42238-021-00114-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s42238-021-00114-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s42238-021-00114-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,4]],"date-time":"2022-01-04T14:17:56Z","timestamp":1641305876000},"score":1,"resource":{"primary":{"URL":"https:\/\/jcannabisresearch.biomedcentral.com\/articles\/10.1186\/s42238-021-00114-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,4]]},"references-count":10,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["114"],"URL":"https:\/\/doi.org\/10.1186\/s42238-021-00114-9","relation":{},"ISSN":["2522-5782"],"issn-type":[{"value":"2522-5782","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,4]]},"assertion":[{"value":"3 August 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 December 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"In the UK, ethics approval is not required for purely registry-based studies. All participants completed written informed consent prior to enrolment in the registry.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All participants completed written informed consent prior to enrolment in the registry. All patients consented to being in the registry and there is no specific identifiable data.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"SE, CH, RC, SK, MP, JJR & MHS are the founding clinicians of Sapphire Medical Clinics, which is the first clinic registered with the CQC to evaluate patients for medical cannabis in England. Full declarations and conflicts of interest are provided at the end of the manuscript.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"3"}}